Experience

Radionetics Oncology Announces Strategic Agreement With Eli Lilly

July 1, 2024

Cooley advised Radionetics Oncology, a biotechnology company discovering and developing novel small molecule G protein-coupled receptor (GPCR)-targeted radiopharmaceuticals to treat a broad range of solid tumors, on the formation of a strategic agreement with Eli Lilly to take forward Radionetics’ proprietary GPCR-targeting small molecule radiopharmaceuticals. Under the terms of the agreement, Radionetics received a $140 million up-front cash payment. Additionally, Lilly obtained the exclusive right to acquire Radionetics for $1 billion upon conclusion of an exercise period.

Read more

Related contacts

Rama Padmanabhan
Partner, San Diego
Charity Williams
Partner, San Diego
Jenny Ge
Associate, Santa Monica
Chen Chen
Associate, Palo Alto
Todd Gluth
Partner, San Diego
Alessandra Murata
Partner, Palo Alto
Ross Eberly
Partner, Santa Monica
Howard Morse
Partner, Washington, DC
Natasha Leskovsek
Of Counsel, Washington, DC
David Burns
Special Counsel, Washington, DC
Andrew Epstein
Special Counsel, Seattle
Karen Tsai
Special Counsel, Washington, DC
Ajay Athavale
Associate, San Francisco
Kyle Hess
Associate, New York
Jonathan Kaufman
Associate, Palo Alto
Allison Kutner
Associate, New York
Edmond Lay
Associate, San Diego
Jeremy Gentile
Associate, San Diego
Amanda Pacheco
Associate, Palo Alto
Breanna Qin
Associate, Palo Alto
Megan Drill
Associate, San Diego
Daniel Gillon
Associate, San Diego
Jack Whitaker
Associate, San Diego
Patricia Myers
Paralegal Specialist, Colorado

Related Practices & Industries

ARCH Venture Partners Co-Leads Xaira Therapeutics $1 Billion Series A Funding

April 24, 2024

Cooley advised ARCH Venture Partners, which co-led a $1 billion Series A funding round in Xaira Therapeutics. Partners Colleen Badgley, Danielle Naftulin and Dave Peinsipp led the Cooley team advising ARCH, a venture capital firm catalyzing discoveries that prevent, detect and cure disease.

Related contacts

David Peinsipp
Partner, San Francisco
Colleen Badgley
Partner, Seattle
Danielle Naftulin
Partner, Palo Alto
Willy Cowles
Associate, Seattle
Bill Christiansen
Partner, Seattle
Dr. Tian Yong Zheng
Patent Agent, Seattle
Chen Chen
Associate, Palo Alto
Bin Wang
Special Counsel, Palo Alto
Zack Gong
Associate, Shanghai
Tom James
Associate, San Francisco
Thomas Welk
Senior Counsel, San Diego
Carly Robinson
Associate, Reston
Sharon Connaughton
Special Counsel, Washington, DC
Elizabeth M. Morrison
Associate, Boston

Related Practices & Industries

MediLink Therapeutics Announces Strategic Collaboration, Worldwide License Agreement With BioNTech

October 12, 2023

Cooley advised MediLink Therapeutics, a clinical-stage biotech company focused on developing globally competitive conjugated drugs, on its strategic research collaboration and worldwide license agreement with BioNTech.

Read more

Related contacts

Lila Hope
Partner, Palo Alto
Chen Chen
Associate, Palo Alto
Jennifer Raab
Partner, Palo Alto
Natasha Leskovsek
Of Counsel, Washington, DC
Amanda Pacheco
Associate, Palo Alto
Sharon Connaughton
Special Counsel, Washington, DC
David Burns
Special Counsel, Washington, DC

Related Practices & Industries

IMPACT Therapeutics Announces Global License Collaboration Agreement With Eikon

June 14, 2023

Cooley advised IMPACT Therapeutics, a biopharmaceutical company dedicated to the discovery and development of targeted anti-cancer innovative drugs based on synthetic lethality on its license and collaboration agreement with Eikon Therapeutics, a biotechnology company.

Read more

Related contacts

Lila Hope
Partner, Palo Alto
Yiming Liu
Partner in Charge – Shanghai, Shanghai
Xiaoyu Xu
Associate, Beijing
Xiaozhen (Shawn) Yu
Associate, Washington, DC
Amanda Pacheco
Associate, Palo Alto
Chen Chen
Associate, Palo Alto

Related Practices & Industries

Zion Pharma Announces Sale of Lead Program to Roche

May 15, 2023

Cooley advised Zion Pharma Limited, a Chinese biotechnology company focused on the development of brain-penetrable compounds, on the acquisition of its lead program, ZN-A-1041, by Roche.

Read more

Related contacts

Lila Hope
Partner, Palo Alto
Yiming Liu
Partner in Charge – Shanghai, Shanghai
Aaron Pomeroy
Partner, Colorado
David Burns
Special Counsel, Washington, DC
Xiaoyu Xu
Associate, Beijing
Amanda Pacheco
Associate, Palo Alto
Chen Chen
Associate, Palo Alto

Related Practices & Industries

View more

Admissions and credentials

California